Teva QVAR Inhaler Settlement: $35 Million for Consumers Who Paid for QVAR or QVAR Redihaler — Claim by July 31, 2026
Teva QVAR Inhaler Antitrust Class Action Settlement
Teva Pharmaceutical has agreed to a $35 million class action settlement over allegations that it unlawfully blocked generic competition for QVAR and QVAR Redihaler inhalers, causing consumers and health plans to overpay. If you purchased, paid for, or reimbursed some or all of the cost of QVAR or QVAR Redihaler in one of 43 listed states or D.C. at any time between January 1, 2015 and July 31, 2025, you may be eligible for a pro rata cash payment. File your claim by July 31, 2026.
Settlement fund
$35M
Common fund
Top payout
Pro rata
Share of $35M fund, based on purchases
Claim deadline
Jul 31, 2026
59 days remaining
You may be owed money
Filing is free and takes a few minutes. Deadline: Jul 31, 2026.
Do you qualify?
You are a Class Member if ALL of the following apply:
- You purchased, paid for, and/or reimbursed some or all of the purchase price of QVAR and/or QVAR Redihaler inhalers at any point between January 1, 2015 and July 31, 2025.
- Your purchase was for your own use, for your family, or for your members, insureds, or beneficiaries (not for resale).
- Your purchase was made in one of the following 43 states or territories: Alaska, Arkansas, Arizona, California, Connecticut, Delaware, D.C., Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Massachusetts, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, West Virginia, Wisconsin, or Wyoming.
- Excluded: Teva and their respective subsidiaries and affiliates; and federal and state governmental entities.
Not sure if you qualify? Call the Settlement Administrator toll-free at 1-866-588-8524, or visit QVARantitrustSettlement.com.
What happened
Plaintiffs allege that Teva took two unlawful steps to keep lower-cost generic versions of QVAR off the market. First, they allege Teva improperly listed certain device patents in the FDA's Orange Book, a database that triggers automatic 30-month delays in generic drug approvals whenever a patent suit is filed. Second, they allege Teva performed a series of "product hops" by discontinuing older inhaler designs and launching new versions to obtain fresh patent protection, a tactic plaintiffs contend was designed to reset the clock on generic competition. The combined effect, according to the lawsuit, was that consumers and health plans paid artificially inflated prices for brand-name QVAR and QVAR Redihaler for a decade.
Teva denies all allegations and denies any wrongdoing or liability. The Court has not ruled that Teva did anything wrong. The parties agreed to settle to avoid the cost, risk, and time of continued litigation. In addition to the $35 million cash fund, Teva has agreed to request removal of certain patents from the FDA's Orange Book, which may help clear the path for future generic competition.
How to file a claim
-
1. Confirm you are eligible
You must have purchased, paid for, or reimbursed QVAR or QVAR Redihaler inhalers between January 1, 2015 and July 31, 2025, for personal or covered use (not for resale), in one of the 43 listed states or D.C. Both individual consumers and third-party payors (health plans, insurers, union health funds) are eligible to file.
-
2. Determine your claim type
Individual consumers file a Consumer Claim Form. Third-party payors (TPPs) such as health plans, insurance companies, or union health funds file a Third-Party Payor Claim Form. The net settlement fund is split: 20.7% goes to the Consumer Fund and 79.3% goes to the Third-Party Payor Fund. Each claimant receives a pro rata share of their respective fund based on their qualifying purchases. The per-person amount is not known in advance and depends on total claim volume.
-
3. File online or by mail
Submit your Claim Form online at QVARantitrustSettlement.com/file-a-claim by July 31, 2026, or mail a paper Claim Form (postmarked by July 31, 2026) to: QVAR Antitrust Settlement, c/o A.B. Data, Ltd., P.O. Box 173034, Milwaukee, WI 53217.
-
4. Receive your payment
Payments are issued after the Court grants final approval at the August 5, 2026 Fairness Hearing and any appeals are resolved. The appeal process can take a year or more. No follow-up is required once your claim is submitted.
Key dates
- Jun 15, 2026 Opt-out & objection deadline Upcoming
- Jul 31, 2026 Claim filing deadline Upcoming
- Aug 5, 2026 Final Fairness Hearing (2:00 p.m. ET, in person (Courtroom 4, Boston, MA)) Upcoming
- TBD after final approval Payments issued to claimants Pending
The Fairness Hearing is scheduled for August 5, 2026 at 2:00 p.m. ET before the Honorable Nathaniel M. Gorton in Courtroom 4 of the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, Massachusetts 02210. The Court may move the hearing, so check QVARantitrustSettlement.com for updates before traveling.
Where the money is going
This is a non-reversionary common fund. Attorneys' fees (up to 33%), litigation expenses (up to $890,000), service awards, and notice/administration costs come out of the $35 million before class member payments are calculated. The remaining net fund is split 20.7% for consumers and 79.3% for third-party payors.
All amounts listed above are pending and subject to final court approval. The Consumer Fund and Third-Party Payor Fund allocations are fixed percentages of the net fund. Individual payouts depend on total claim volume and each claimant's qualifying purchases relative to the full class.
Common questions
How much money will I receive?
Your payment will be a pro rata share of either the Consumer Fund (20.7% of the net settlement fund) or the Third-Party Payor Fund (79.3% of the net fund), depending on your claim type. The amount is proportional to your QVAR and QVAR Redihaler purchases during the January 1, 2015 to July 31, 2025 class period relative to all valid claims filed. The Notice does not state a specific per-person dollar amount, and actual payments will depend on total claim volume. After attorneys' fees, expenses, and administration costs are deducted, the net fund is divided between the two claimant pools.
Do I need to submit proof of purchase?
The public Notice and website do not list specific receipt or purchase-documentation requirements for consumer claims. Consumer claims are submitted with confidentiality protections and your identity is not made public unless you consent. Third-party payors will need to substantiate their reimbursement data. Review the Claim Form at QVARantitrustSettlement.com/file-a-claim for specific data fields before submitting.
What if I didn’t receive a notice?
Yes. You do not need to have received a mailed Notice to file a claim. If you purchased, paid for, or reimbursed QVAR or QVAR Redihaler in one of the 43 listed states or D.C. between January 1, 2015 and July 31, 2025 for personal or covered use, you are likely a Class Member. Notice was distributed through multiple channels including mail and publication, but not all class members receive direct notice. Visit QVARantitrustSettlement.com or call 1-866-588-8524 with questions.
Does staying in the class affect my right to sue later?
Yes. Unless you mail or email a written exclusion request to the Settlement Administrator by June 15, 2026, you will be bound by the Settlement and you release your legal claims against Teva related to the conduct at issue in this lawsuit. That means you cannot sue Teva separately for the same alleged conduct. To opt out, email info@QVARantitrustsettlement.com or mail your written exclusion request to: QVAR Antitrust Settlement - EXCLUSIONS, c/o A.B. Data, Ltd., P.O. Box 173001, Milwaukee, WI 53217, postmarked by June 15, 2026.
When will payments be sent out?
The Court will hold the Fairness Hearing on August 5, 2026 at 2:00 p.m. ET before Judge Nathaniel M. Gorton in Boston. Payments will only be issued after the Court grants final approval and any appeals are resolved. The appeal process can take a year or more. No action is required after a valid Claim Form is submitted; check QVARantitrustSettlement.com for updates.
Dapeer Law, P.A.
Consumer class action attorneys based in South Florida. We track settlements so you don’t have to.
Similar open settlements
This page is for informational purposes only and does not constitute legal advice. Dapeer Law, P.A. is not the administrator of this settlement and is not affiliated with Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc.; Teva Branded Pharmaceutical Products R&D LLC; and Norton (Waterford) Ltd., A.B. Data, Ltd. (the Settlement Administrator), or Class Counsel Todd A. Seaver of Berman Tabacco, Joseph Vanek of Sperling Kenny Nachwalter, LLC, and Steve Shadowen of Hilliard Shadowen LLP. The case is Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., Case No. 1:23-cv-11131-NMG, pending in the U.S. District Court for the District of Massachusetts before the Honorable Nathaniel M. Gorton. Class representatives are Iron Workers District Council of New England Health and Welfare Fund, Utah-Idaho Teamsters Security Fund, Jacksonville Police Officers and Fire Fighters Health Insurance Trust, and NYST Council Health & Hospital Fund. Teva denies wrongdoing. This website is attorney advertising. Past results do not guarantee future outcomes.
